Sotrovimab retains activity against SARS-CoV-2 omicron variant BQ.1.1 in a non-human primate model
Description
The SARS-CoV2 Omicron variants have acquired new Spike mutations leading to escape from the most of the currently available monoclonal antibody treatments reducing the options for patients suffering from severe Covid-19. Recently, both in vitro and
